Nisa Investment Advisors LLC Has $23.41 Million Holdings in Edwards Lifesciences Corp (EW)

Nisa Investment Advisors LLC increased its holdings in Edwards Lifesciences Corp (NYSE:EW) by 6.0% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 122,330 shares of the medical research company’s stock after acquiring an additional 6,897 shares during the period. Nisa Investment Advisors LLC owned approximately 0.06% of Edwards Lifesciences worth $23,405,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Capital Insight Partners LLC increased its position in shares of Edwards Lifesciences by 0.5% during the first quarter. Capital Insight Partners LLC now owns 11,010 shares of the medical research company’s stock worth $2,107,000 after purchasing an additional 53 shares in the last quarter. Cetera Advisor Networks LLC increased its position in shares of Edwards Lifesciences by 3.8% during the fourth quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock worth $242,000 after purchasing an additional 57 shares in the last quarter. Kentucky Retirement Systems increased its position in shares of Edwards Lifesciences by 0.7% during the fourth quarter. Kentucky Retirement Systems now owns 9,093 shares of the medical research company’s stock worth $1,393,000 after purchasing an additional 60 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Edwards Lifesciences by 11.2% during the fourth quarter. Parallel Advisors LLC now owns 684 shares of the medical research company’s stock worth $101,000 after purchasing an additional 69 shares in the last quarter. Finally, BB&T Securities LLC increased its position in shares of Edwards Lifesciences by 0.9% during the fourth quarter. BB&T Securities LLC now owns 8,179 shares of the medical research company’s stock worth $1,252,000 after purchasing an additional 70 shares in the last quarter. Institutional investors own 84.62% of the company’s stock.

Shares of EW opened at $181.34 on Friday. The firm has a market capitalization of $37.22 billion, a price-to-earnings ratio of 38.58, a price-to-earnings-growth ratio of 2.32 and a beta of 0.85. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.66 and a quick ratio of 2.69. Edwards Lifesciences Corp has a fifty-two week low of $134.38 and a fifty-two week high of $197.86.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.09. The business had revenue of $993.00 million during the quarter, compared to the consensus estimate of $989.87 million. Edwards Lifesciences had a return on equity of 31.16% and a net margin of 20.03%. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.22 EPS. On average, analysts forecast that Edwards Lifesciences Corp will post 5.28 EPS for the current year.

A number of analysts have recently commented on EW shares. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $180.00 to $190.00 in a research report on Friday, January 18th. Raymond James lowered their price target on Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday, April 24th. Barclays raised their price target on Edwards Lifesciences from $150.00 to $160.00 and gave the stock an “underweight” rating in a report on Monday, March 25th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $180.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Finally, UBS Group lifted their price objective on Edwards Lifesciences from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Tuesday, March 12th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the stock. Edwards Lifesciences has an average rating of “Buy” and a consensus price target of $187.00.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 1,474 shares of the company’s stock in a transaction dated Thursday, February 21st. The shares were sold at an average price of $176.34, for a total value of $259,925.16. Following the completion of the transaction, the vice president now directly owns 15,905 shares of the company’s stock, valued at approximately $2,804,687.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of the company’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $177.75, for a total transaction of $977,625.00. Following the completion of the transaction, the vice president now directly owns 24,482 shares of the company’s stock, valued at $4,351,675.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 152,437 shares of company stock valued at $26,836,405. 1.63% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/10/edwards-lifesciences-corp-ew-shares-bought-by-nisa-investment-advisors-llc.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: Liquidity

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.